Physician profile
Michael J Mclaughlin
NPI 1679534648
$3,894.43
in general payments reported to CMS, 2019-2025
14 companies · $914 in 2025
The $914 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $293 · 2021: $1,735 · 2023: $322 · 2024: $387 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $860 · Food and Beverage: $656 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $860.00 |
| Food and Beverage | $655.64 |
| Education | $107.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $1,465.64 | 2020-2021 | |
| Incyte Corporation | $860.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $652.79 | 2019-2023 | Tagrisso |
| Janssen Biotech, INC. | $240.83 | 2024 | Tecvayli, Darzalex, Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $165.56 | 2019-2020 | |
| Tactile Systems Technology INC | $146.16 | 2024 | Flexitouch Plus, Entre Plus |
| E.R. Squibb & Sons, L.L.C. | $115.57 | 2023 | Opdivo |
| Comsort, INC | $100.00 | 2019 | |
| Aveo Pharmaceuticals, INC. | $81.99 | 2023 | Fotivda |
| Tempus Ai, INC | $28.27 | 2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Welireg |
| Gilead Sciences, INC. | $11.92 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.